No Data
tibet rhodiola pharmaceutical holding (600211.SH): is currently participating in the application for the continuation of the fourth to fifth batch of national centralized drug procurement agreement expiration varieties by jiangsu alliance.
Gelonghui November 4th, Tibet Rhodiola Pharmaceutical Holding (600211.SH) stated at the performance briefing that the company is currently participating in the application work for the continued procurement of the 4th-5th batch of nationally organized pharmaceutical centralized procurement agreement-expired varieties by the jiangsu alliance. Please pay attention to the official website of the Jiangsu Provincial Medical Security Bureau for specific results.
Tibet Nordicang Pharmaceutical Co., Ltd. Report for the third quarter of 2024
tibet rhodiola pharmaceutical holding (600211.SH) released its performance for the first three quarters, with a net income of 0.792 billion yuan, a 7.42% year-on-year decrease.
tibet rhodiola pharmaceutical holding (600211.SH) released the third quarter report for 2024, with revenue for the first three quarters reaching...
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The net income for the first three quarters was 0.792 billion yuan, a year-on-year decrease of 7.42%.
On October 29th, Gelonhui reported the third quarter of 2024 of Tibet Rhodiola Pharmaceutical Holding (600211.SH). The company's revenue for the first three quarters was 2.175 billion yuan, a decrease of 8.13% year-on-year; the net income attributable to the shareholders of the listed company was 0.792 billion yuan, a decrease of 7.42% year-on-year; and the basic earnings per share was 2.46 yuan.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): Currently, there is no application for a loan to repurchase stocks plan.
Galaxy Today | Tibet Rhodiola Pharmaceutical Holding (600211.SH) stated on the investor interaction platform that the company currently has no plans to apply for loans to buy back stocks. In the future, the company will carefully consider in combination with market conditions and the actual situation of the company, and actively make decisions that are beneficial to the company's development.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): Yimdoo (China market) has obtained a supplementary application approval for pharmaceuticals.
On October 14, Tibet Rhodiola Pharmaceutical Holding (600211.SH) announced that its wholly-owned subsidiary Tibet Nordicon Technology Development Co., Ltd. recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. The drug's multifunctional treatment includes: long-term treatment of coronary heart disease, prevention of vasospastic and mixed angina, as well as long-term treatment of chronic heart failure after myocardial infarction. In 2023, the sales volume of Emuduo was 9.4906 million boxes (equivalent to 60mg), with revenue of 0.13 billion yuan, accounting for 4% of our company's main business income in 2023.
No Data
No Data